Mitomycin C (Synonyms: Ametycine) |
Catalog No.GC12353
One-Click Copy Product Info
|
Mitomycin C is a cytotoxic antitumor antibiotic.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 50-07-7
Sample solution is provided at 25 µL, 10mM.
- Cancer Cell Int 22.1 (2022):312.PMID:36224624
- Microbiol Res (2025):128123.PMID:40037110
- Cell Death Discov 11.1 (2025):1-16.
- Cell Biol Toxicol (2026).PMID:42340494
- Front Endocrinol 17 (2026):1807887.PMID:42388858
- J Ethnopharmacol (2024):117869.PMID:38342153
- J Mol Med (2024):1-16.PMID:39316093
- Foods 15.12 (2026):2066.
- Iscience: (2026).PMID:42662403
- Mol Biotechnol (2023):1-8.PMID:36917402
- Immunology Letters (2025):106977.PMID:39921064
- Cell Death Dis 12.4 (2021):1-15.
- STAR protocols 2.3 (2021):100789.
- Front Cardiovasc Med 9 (2022).
- Cells 11.19 (2022):2951.
- Theriogenology (2024).
Mitomycin C is a cytotoxic antitumor antibiotic. Mitomycin C undergoes enzymatic reductive activation and then alkylates guanine residues in DNA to form intra-strand and inter-strand crosslinks. Mitomycin C inhibits DNA synthesis and degrades DNA. Mitomycin C can be used in research related to gastric cancer, colorectal cancer, anal canal cancer, bladder cancer, pancreatic cancer, breast cancer, as well as bacterial biofilms and drug-resistant infections[1-4].
In vitro, J82 cells and mitoxantrone-resistant J82/MMC cells were treated with 0.025-10µg/mL Mitomycin C for 24 hours. Mitomycin C reduced J82 cell viability and showed relative resistance in J82/MMC cells[5]. Human non-small cell lung cancer cells (H460, A549, H1299) were treated with 0.4µM Mitomycin C for 24 hours. Mitomycin C increased PD-L1 and MHC-I mRNA and protein expression, and promoted c-JUN binding to the PD-L1 promoter and c-JUN/STAT3 interaction[6]. T24 cells were treated with 0.05-50μM Mitomycin C for 24-48 hours. Mitomycin C reduced cell viability, arrested the cell cycle at the G2/M phase, and decreased the proportion of cells in S phase[7].
In vivo, foxn1nu mice were intraperitoneally injected with 2.5×10⁶ B76 human high-grade serous ovarian cancer cells. Four days later, a 30-minute intraperitoneal perfusion with 20μg/mL Mitomycin C was performed at a flow rate of 6mL/min with a total volume of 30mL. Mitomycin C inhibited peritoneal tumor growth and prolonged median survival[8]. C3H/HeN mice were intraperitoneally injected with a single dose of 1-3mg/kg Mitomycin C. Mitomycin C induced tumoricidal activity in peritoneal macrophages and increased macrophage uptake of 2-deoxy-D-glucose[9]. BALB/c athymic nude mice bearing WiDr human colon adenocarcinoma xenografts were intraperitoneally injected with a single dose of 1-5mg/kg Mitomycin C. Mitomycin C increased the proportion of S-phase cells within the tumor[10].
References:
[1] den Hartigh J, Verweij J, Pinedo HM. Mitomycin C. Cancer Chemother Biol Response Modif. 1988;10:45-9.
[2] Bradner WT. Mitomycin C: a clinical update. Cancer Treat Rev. 2001 Feb;27(1):35-50.
[3] Crespo MA, Rapuano CJ, Syed ZA. Applications of Mitomycin C in Cornea and External Disease. Turk J Ophthalmol. 2023 Jun 21;53(3):175-182.
[4] Di Felice C, Machuzak MS, Shepherd RW. Use of Mitomycin-C in Laryngotracheal Stenosis: A Focused Clinical Review. J Bronchology Interv Pulmonol. 2023 Jul 1;30(3):223-231.
[5] Datta SN, Allman R, Loh C, et al. Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. British Journal of Cancer. 1997;76(3):312-7.
[6] Luo M, Wang F, Zhang H, et al. Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. Signal Transduction and Targeted Therapy. 2020 Aug 28;5:141.
[7] Nakayama T, Nozawa N, Kawada C, et al. Mitomycin C-induced cell cycle arrest enhances 5-aminolevulinic acid-based photodynamic therapy for bladder cancer. Photodiagnosis and Photodynamic Therapy. 2020 Sep;31:101893.
[8] Andersson Y, Lovstakken E, Herud TM, et al. Intraperitoneal perfusion with cisplatin or mitomycin C improves survival in mice bearing peritoneal metastases from ovarian cancer. Annals of Surgical Oncology. 2025;32:9333-40.
[9] Shindo H, Ogura T, Masuno T, et al. Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice. Cancer Immunology Immunotherapy. 1985;20:145-50.
[10] Ma LW, Moan J, Steen HB, et al. Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma. British Journal of Cancer. 1995;71(5):950-6.
| Cell experiment [1]: | |
|
Cell lines |
H460, A549, H1299 cells (human non-small cell lung cancer cell line) |
|
Preparation Method |
H460, A549 and H1299 cells were maintained in RPMI-1640 supplemented with 10% FBS at 37°C, 5% CO2. Cells were treated with 0.4µM Mitomycin C for 24 or 48 hours. After treatment, MTT assay, RT-qPCR, Western blot, luciferase reporter assay, chromatin immunoprecipitation assay, flow cytometric analysis of PD-L1 and MHC-I surface expression, co-culture with PBMCs and LDH release assay, T-cell-mediated tumor killing assay, and granzyme B/TNF-α intracellular staining were performed. |
|
Reaction Conditions |
0.4µM; 24h or 48h |
|
Applications |
Mitomycin C increased PD-L1 and MHC-I mRNA and protein levels, increased p-ERK, p-JNK, p65, p-p65, c-JUN, p-c-JUN, STAT3 and p-STAT3 protein levels, enhanced c-JUN binding to PD-L1 promoter and c-JUN/STAT3 interaction, increased PD-L1 promoter luciferase activity, and after 24h pretreatment enhanced PBMC-mediated lysis of H460 cells, reduced surviving H460 cell viability in PD-L1 antibody co-culture system. |
| Animal experiment [2]: | |
|
Animal models |
Female athymic nude foxn1nu mice (6-8 weeks old) |
|
Preparation Method |
Mice were intraperitoneally injected with 2.5×10⁶ B76 human high-grade serous ovarian cancer GFP/luciferase cells in 500µL. Four days later, a closed peritoneal perfusion circuit was established and mice received a 30-minute intraperitoneal perfusion with 20µg/mL Mitomycin C in 30mL total perfusate at 41°C (HIPEC) or 37°C (NIPEC) with flow rate 6mL/min, followed by 3-minute saline flush. Luminescence imaging was performed serially; some mice were sacrificed on day 17 for tumor weight measurement; survival was recorded until spontaneous endpoint. |
|
Dosage form |
20µg/mL; i.p. perfusion; 30min (single procedure at day 4 after tumor inoculation) |
|
Applications |
Mitomycin C perfusion inhibited intraperitoneal tumor growth, reduced day-17 tumor weight to 0.12g (HIPEC) or 0.28g (NIPEC) versus 0.77g in saline control, lowered luminescence signal, and increased median overall survival from 25 days (saline) to 37 days (HIPEC) or 34 days (NIPEC); hyperthermia addition did not further improve survival. |
References: [1] Luo M, Wang F, Zhang H, et al. Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. Signal Transduction and Targeted Therapy. 2020 Aug 28;5:141. [2] Andersson Y, Lovstakken E, Herud TM, et al. Intraperitoneal perfusion with cisplatin or mitomycin C improves survival in mice bearing peritoneal metastases from ovarian cancer. Annals of Surgical Oncology. 2025;32:9333-40. | |
| Cas No. | 50-07-7 | SDF | |
| Synonyms | Ametycine | ||
| Chemical Name | ((1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl carbamate | ||
| Canonical SMILES | NC(C1=O)=C(C)C(C2=C1[C@@H](COC(N)=O)[C@]3(OC)N2C[C@H]4[C@@H]3N4)=O | ||
| Formula | C15H18N4O5 | M.Wt | 334.33 |
| Solubility | ≥ 16.7mg/mL in DMSO | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9911 mL | 14.9553 mL | 29.9106 mL |
| 5 mM | 598.2 μL | 2.9911 mL | 5.9821 mL |
| 10 mM | 299.1 μL | 1.4955 mL | 2.9911 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)